Iovance Biotherapeutics, Inc. (IOVA) experienced a significant pre-market surge of 5.29% on Wednesday, indicating strong investor interest ahead of the regular trading session.
The sharp increase appears to be driven by positive analyst coverage, with Barclays maintaining a Buy rating on the stock and setting a price target of $11.00. This endorsement from a major financial institution likely boosted investor confidence in the biotechnology company's prospects.